ARWR
ARROWHEAD PHARMACEUTICALS IN
Latest close $90.07 as of Aug 5, 2026
Schedule 13G/13D reports beneficial ownership at an observation date. “Accumulation” or “reduction” is inferred
from changes in reported shares when available; it is not a list of individual trades or exact execution prices.
Form 13F rows are quarter-end holding context only and do not establish an exact entry date.
Free access includes current parsed ownership filings, reported share changes, and ownership-percentage changes.
Significance scoring, disclosure-speed analysis, confirmation/divergence signals, and signal alerts require Investor or Pro.
Compare plans.
Beneficial ownership filing history
Showing 3 of 5 parsed filing(s) · 2 older require more history access| Holder | Observed / filed | Reported change | Shares | Ownership | Observation | Filing | Latest |
|---|---|---|---|---|---|---|---|
| BlackRock CIK0002012383 | Jun 30, 2026 observed Jul 27, 2026 filed · 27d Schedule 13G amendment | Reported reduction | 14.2M -2.9M | 12.00% -0.20 pts | $81.51 | $85.53 | $90.07 |
| BlackRock CIK0002012383 | Mar 31, 2026 observed Apr 24, 2026 filed · 24d Schedule 13G amendment | Reported reduction | 17.1M -3.2M | 12.20% -2.80 pts | $62.70 | $73.91 | $90.07 |
| BlackRock CIK0002012383 | Dec 31, 2025 observed Jan 21, 2026 filed · 21d Schedule 13G amendment | Earliest Schedule 13G amendment found | 20.3M | 15.00% | $67.60 | $90.07 |